Meeting Banner
Abstract #3194

Glutamate imaging in schizophrenia prodrome

Zhuozhi Dai1,2, Handi Zhang3, Alan H. Wilman1, Haiyun Xu3, Gang Xiao4, Hongfu Sun5, Zerui Zhuang6, Yanlong Jia6, Zhiwei Shen6, Gen Yan7, and Renhua Wu6

1University of Alberta, Edmonton, AB, Canada, 2Radiology, 2nd Affiliated Hospital of Shantou University Medical College, Shantou, China, 3Mental Health Center of Shantou University, Shantou, China, 4Mathematics and Information Technology, Hanshan Normal University, Chaozhou, China, 5Hotchkiss Brain Institute, Calgary, AB, Canada, 62nd Affiliated Hospital of Shantou University Medical College, Shantou, China, 7Affiliated Hospital of Jiangnan University, Wuxi, China

The diagnosis of schizophrenia prodrome is significant since early intervention may prevent the development of full-blown schizophrenia. With increasing evidence indicating that glutamate is involved in the incidence of schizophrenia, we hypothesize that glutamate could be an imaging biomarker in the diagnosis of prodromal schizophrenia. We applied the glutamate CEST imaging technique in schizophrenic models and demonstrates that glutamate changes in different regions of the brain at an early stage, which may provide a powerful indicator of the diagnosis of schizophrenia prodrome. In addition, the glutamate CEST image had excellent correlation with standard MR spectroscopy.

This abstract and the presentation materials are available to members only; a login is required.

Join Here